BIO trades 7.6% above Wall Street's consensus target of $350.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BIO achieves its forward estimates and maintains a stable P/E multiple of 39.3x. This scenario reflects the blended consensus of 14 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Bio-Rad Laboratories, Inc. (BIO) has a Wall Street consensus price target of $350.00, based on estimates from 14 covering analysts. With the stock currently trading at $378.88, this represents a potential downside of -7.6%. The company has a market capitalization of $10.20B.
Analyst price targets range from a low of $310.00 to a high of $390.00, representing a 23% spread in expectations. The median target of $350.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BIO trades at a trailing P/E of 13.6x and forward P/E of 39.3x. Analysts expect EPS to grow +16.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TMOThermo Fisher Scientific Inc. | $247.2B | $665.30 | $623.36 | -6.3% | Buy | 26.5x | 43 |
 DHRDanaher Corporation | $155.9B | $221.70 | $223.77 | +0.9% | Buy | 26.1x | 43 |
 BRKRBruker Corporation | $9.1B | $59.67 | $59.50 | -0.3% | Buy | 28.1x | 33 |
 RGENRepligen Corporation | $10.4B | $184.53 | $162.43 | -12.0% | Buy | 89.5x | 24 |
 CRLCharles River Laboratories International, Inc. | $13.4B | $277.33 | $282.36 | +1.8% | Buy | 24.5x | 37 |
 IDXXIDEXX Laboratories, Inc. | $41.2B | $522.02 | $665.00 | +27.4% | Buy | 35.3x | 23 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 QGENQiagen N.V. | $9.0B | $43.71 | $43.01 | -1.6% | Hold | 18.0x | 30 |
 AZTAAzenta, Inc. | $1.6B | $34.09 | $43.00 | +26.1% | Buy | 93.8x | 12 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
Quick answers to the most common questions about buying BIO stock.
Wall Street's consensus price target for BIO is $350, -7.6% from its current price of $378.88. The below-market target from 14 analysts suggests limited near-term appreciation.
BIO has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $350 implies -7.6% downside from current levels.
At a forward P/E of 39.3009x, BIO trades at a premium valuation. The consensus price target of $350 (-7.6% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $390 for BIO, while the most conservative target is $310. The consensus of $350 represents the median expectation. These targets typically reflect 12-month expectations.
BIO is moderately covered, with 14 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 7 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BIO stock forecast based on 14 Wall Street analysts shows a consensus price target of $350, with estimates ranging from $310 (bear case) to $390 (bull case). The median consensus rating is "Buy".
BIO trades at a forward P/E ratio of 39.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 13.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on BIO, with 0 Sell ratings and a price target of $350 (-7.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BIO analyst price targets range from $310 to $390, a 23% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $350 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.